HER-2阳性乳腺癌的辅助治疗和新辅助治疗

The adjuvant and neo-adjuvant chemotherapy of HER-2 positive breast cancer

乳腺癌已经从群体治疗走向个体化治疗,其中HER-2状态是判断患者生存预后的重要指标.如何准确判断HER-2状态以及确诊后早期阶段患者该如何选择靶向治疗,尽管已存在不少指南与共识,但仍然需要不断推广和普及.我们从HER-2状态的标准检测及靶向治疗的选择出发,阐述早期HER-2阳性乳腺癌患者的治疗准则与经验.

The therapy of breast cancer has developed into indi- vidual therapies, while the real HER-2 status is an important index to judge the prognosis of the patients. How to accurately identify the HER-2 status, and then to choose an appropriate targeted therapy are still need to spread and popularize continuously. From this perspective, the standard testing of HER-2 status, the possible choice of targeted therapy, and the treatment experience for HER-2 positive breast cancer are reviewed.